Brooklyn ImmunoTherapeutics Inc
ASE:BTX 3:59:35 PM EDT
Brooklyn ImmunoTherapeutics Inc Stock, ASE:BTX
1040 1st Avenue, Suite 361, New York, New York 10022
United States of America
Phone: +1.212.582.1199
Number of Employees: 22
Description
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.